PRINCIPIA BIOPHARMA INC. Research and Development Expense
PRINCIPIA BIOPHARMA INC. reported Research and Development Expense of $30.89 million for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-08-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2020-08-06
- PRINCIPIA BIOPHARMA INC. research and development expense for the quarter ending 2020-06-30 was $30.89M, a 65.02% increase year-over-year.
- PRINCIPIA BIOPHARMA INC. research and development expense for the quarter ending 2020-03-31 was $26.74M, a 72.27% increase year-over-year.
- PRINCIPIA BIOPHARMA INC. research and development expense for the quarter ending 2019-12-31 was $21.47M, a 57.00% increase year-over-year.
- PRINCIPIA BIOPHARMA INC. research and development expense for the quarter ending 2019-09-30 was $18.37M, a 99.65% increase year-over-year.
- PRINCIPIA BIOPHARMA INC. research and development expense for fiscal 2019 was $74.08M, a 82.77% increase from fiscal 2018.
- PRINCIPIA BIOPHARMA INC. research and development expense for fiscal 2018 was $40.53M, a 59.64% increase from fiscal 2017.
- PRINCIPIA BIOPHARMA INC. research and development expense for fiscal 2017 was $25.39M, a 13.91% increase from fiscal 2016.
- PRINCIPIA BIOPHARMA INC. research and development expense for fiscal 2016 was $22.29M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2020-06-30 | $30.89M 10-Q · filed 2020-08-06 | $57.63M 10-Q · filed 2020-08-06 | $79.10M derived: sum of 3 quarters · filed 2020-08-06 | $97.47M derived: sum of 4 quarters · filed 2020-08-06 |
| 2020-03-31 | $26.74M 10-Q · filed 2020-05-06 | $48.22M derived: sum of 2 quarters · filed 2020-05-06 | $66.58M derived: sum of 3 quarters · filed 2020-05-06 | $85.30M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-12-31 | $21.47M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $39.84M derived: sum of 2 quarters · filed 2020-03-10 | $58.56M derived: sum of 3 quarters · filed 2020-08-06 | $74.08M 10-K · filed 2020-03-10 |
| 2019-09-30 | $18.37M 10-Q · filed 2019-11-05 | $37.09M derived: sum of 2 quarters · filed 2020-08-06 | $52.61M 10-Q · filed 2019-11-05 | $66.29M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-06-30 | $18.72M 10-Q · filed 2020-08-06 | $34.24M 10-Q · filed 2020-08-06 | $47.92M derived: sum of 3 quarters · filed 2020-08-06 | $57.12M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $15.52M 10-Q · filed 2020-05-06 | $29.20M derived: sum of 2 quarters · filed 2020-05-06 | $38.40M derived: sum of 3 quarters · filed 2020-05-06 | $47.30M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $13.68M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $22.88M derived: sum of 2 quarters · filed 2020-03-10 | $31.77M derived: sum of 3 quarters · filed 2020-03-10 | $40.53M 10-K · filed 2020-03-10 |
| 2018-09-30 | $9.20M 10-Q · filed 2019-11-05 | $18.09M derived: sum of 2 quarters · filed 2019-11-05 | $26.86M 10-Q · filed 2019-11-05 | $34.40M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-06-30 | $8.89M 10-Q · filed 2019-08-08 | $17.66M 10-Q · filed 2019-08-08 | $25.20M derived: sum of 3 quarters · filed 2020-03-10 | $31.26M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-03-31 | $8.76M 10-Q · filed 2019-05-07 | $16.30M derived: sum of 2 quarters · filed 2020-03-10 | $22.36M derived: sum of 3 quarters · filed 2020-03-10 | |
| 2017-12-31 | $7.54M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $13.60M derived: sum of 2 quarters · filed 2020-03-10 | $25.39M 10-K · filed 2020-03-10 | |
| 2017-09-30 | $6.06M 10-Q · filed 2018-11-06 | $17.85M 10-Q · filed 2018-11-06 | ||
| 2016-12-31 | $22.29M 10-K · filed 2019-03-19 |